Browsing by Author "Anderson, Kenneth"

Now showing items 1-20 of 32

    • Advances in the Treatment of Monoclonal Gammopaties: The Emerging Role of Targeted Therapy in Plasma Cell Dyscrasias 

      Roccaro, Aldo M.; Ghobrial, Irene; Blotta, Simona; Treon, Steven P.; Malagola, Michele; Anderson, Kenneth Carl; Russo, Domenico (Dove Medical Press, 2008)
      The paradigm for the treatment of monoclonal gammopaties has dramatically changed: therapeutic options in multiple myeloma (MM) have evolved from the introduction of melphalan and prednisone in the 1960s, high-dose ...

    • APRIL Signaling via TACI Mediates Immunosuppression by T Regulatory Cells in Multiple Myeloma: Therapeutic Implications 

      Tai, Yu-Tzu; Lin, Liang; Xing, Lijie; Cho, Shih-Feng; Yu, Tengteng; Acharya, Chirag; Wen, Kenneth; Hsieh, Phillip A.; Dulos, John; van Elsas, Andrea; Munshi, Nikhil; Richardson, Paul; Anderson, Kenneth (Springer Science and Business Media LLC, 2019-02-01)
      We here investigate how APRIL impacts immune regulatory T cells and directly contributes to the immunosuppressive multiple myeloma (MM) bone marrow (BM) microenvironment. First, APRIL receptor TACI expression is significantly ...

    • Class IIa HDAC inhibition enhances ER stress-mediated cell death in multiple myeloma 

      Kikuchi, Shohei; Suzuki, Rikio; Ohguchi, Hiroto; Yoshida, Yashiro; Lu, Duo; Cottini, Francesca; Jakubikova, Jana; Bianchi, Giada; Harada, Takeshi; Gorgun, Guliu; Tai, Yu-Tzu; Richardson, Paul Gerard Guy; Hideshima, Teru; Anderson, Kenneth Carl (Springer Science and Business Media LLC, 2015-03-24)
      Histone deacetylase (HDAC) inhibitors have been extensively investigated as therapeutic agents in cancer. However, the biologic role of class IIa HDACs (HDAC4, 5, 7 and 9) in cancer cells, including multiple myeloma (MM), ...

    • Clonal Architecture of CXCR4 WHIM-Like Mutations in Waldenström Macroglobulinaemia 

      Xu, Lian; Hunter, Zachary; Tsakmaklis, Nicholas; Cao, Yang; Yang, Guang; Chen, Jie; Liu, Xia; Kanan, Sandra; Castillo, Jorge; Tai, Yu-Tzu; Zehnder, James L.; Brown, Jennifer; Carrasco, Ruben; Advani, Ranjana; Sabile, Jean M.; Argyropoulos, Kimon; Lia Palomba, M.; Morra, Enrica; Trojani, Alessandra; Greco, Antonino; Tedeschi, Alessandra; Varettoni, Marzia; Arcaini, Luca; Munshi, Nikhil; Anderson, Kenneth; Treon, Steven (Wiley, 2016-03)
      CXCR4WHIM somatic mutations are distinctive to Waldenstrom Macroglobulinaemia (WM), and impact disease presentation and treatment outcome. The clonal architecture of CXCR4WHIM mutations remains to be delineated. We developed ...

    • Combination of a Selective HSP90α/β Inhibitor and a RAS-RAF-MEK-ERK Signaling Pathway Inhibitor Triggers Synergistic Cytotoxicity in Multiple Myeloma Cells 

      Suzuki, Rikio; Kikuchi, Shohei; Harada, Takeshi; Mimura, Naoya; Minami, Jiro; Ohguchi, Hiroto; Yoshida, Yasuhiro; Sagawa, Morihiko; Gorgun, Gullu; Cirstea, Diana; Cottini, Francesca; Jakubikova, Jana; Tai, Yu-Tzu; Chauhan, Dharminder; Richardson, Paul G.; Munshi, Nikhil; Ando, Kiyoshi; Utsugi, Teruhiro; Hideshima, Teru; Anderson, Kenneth C. (Public Library of Science, 2015)
      Heat shock protein (HSP)90 inhibitors have shown significant anti-tumor activities in preclinical settings in both solid and hematological tumors. We previously reported that the novel, orally available HSP90α/β inhibitor ...

    • The Cyclophilin A-CD147 complex promotes bone marrow colonization of B-cell malignancies: implications for therapy 

      Zhu, Di; Wang, Zhongqiu; Zhao, Jian-Jun; Calimeri, Teresa; Meng, Jiang; Hideshima, Teru; Fulciniti, Mariateresa; Kang, Yue; Ficarro, Scott; Tai, Yu-Tzu; Hunter, Zachary; McMilin, Douglas; Tong, Haoxuan; Mitsiades, Constantine S.; Wu, Catherine; Treon, Steven; Dorfman, David M.; Pinkus, Geraldine; Munshi, Nikhil; Tassone, Pierfrancesco; Marto, Jarrod; Anderson, Kenneth; Carrasco, Ruben D. (2015)
      B-cell malignancies frequently colonizes the bone marrow (BM). The mechanisms responsible for this preferential homing are not entirely known. Using multiple myeloma (MM) as a model of a terminally differentiated B-cell ...

    • Development and Preclinical Validation of a Novel Covalent Ubiquitin Receptor Rpn13 Degrader in Multiple Myeloma 

      Song, Yan; Wu, Lei; Ray, Arghya; Li, Deyao; Du, Ting; Qi, Jun; Chauhan, Dharminder; Park, Paul; Picaud, Sarah; Wimalasena, Virangika; Filippakopoulos, Panagis; Anderson, Kenneth (Springer Science and Business Media LLC, 2019-04-08)
      Proteasome inhibition is an effective treatment for multiple myeloma (MM); however, targeting different components of the ubiquitin–proteasome system (UPS) remains elusive. Our RNA-interference studies identified ...

    • The Differentiation and Stress Response Factor XBP-1 Drives Multiple Myeloma Pathogenesis 

      Carrasco, Daniel R.; Sukhdeo, Kumar; Protopopova, Marina; Enos, Miriam; Zheng, Mei; Mani, Mala; Ivanova, Elena V.; Tonon, Giovanni; Sinha, Raktim; Carrasco, Daniel E.; Henderson, Joel Michael; Pinkus, Geraldine Sowinski; Munshi, Nikhil C; Horner, James W.; Protopopov, Alexei; Anderson, Kenneth Carl; DePinho, Ronald A. (Cell Press, 2007)
      Multiple myeloma (MM) evolves from a highly prevalent premalignant condition termed MGUS. The factors underlying the malignant transformation of MGUS are unknown. We report a MGUS/MM phenotype in transgenic mice with ...

    • Dynamic Transcriptional Reprogramming Leads to Immunotherapeutic Vulnerabilities in Myeloma 

      Frede, Julia; Anand, Praveen; Sotudeh, Noori; Pinto, Ricardo A.; Nair, Monica S.; Stuart, Hannah; Yee, Andrew J.; Vijaykumar, Tushara; Waldschmidt, Johannes M.; Potdar, Sayalee; Kloeber, Jake A.; Kokkalis, Antonis; Dimitrova, Valeriya; Mann, Mason; Laubach, Jacob; Richardson, Paul; Anderson, Kenneth; Raje, Noopur; Knoechel, Birgit; Lohr, Jens (Springer Science and Business Media LLC, 2021-10-21)

    • HDAC3 regulates DNMT1 expression in multiple myeloma: therapeutic implications 

      Harada, Takeshi; Ohguchi, Hiroto; Grondin, Yohann Renald; Kikuchi, Shannon Adele; Sagawa, Morihiko; Tai, Y-T; Mazitschek, Ralph; Hideshima, Teru; Anderson, Kenneth Carl (Springer Science and Business Media LLC, 2017-05-11)
      Epigenetic signaling pathways are implicated in tumorigenesis and therefore histone deacetylases (HDACs) represent novel therapeutic targets for cancers, including multiple myeloma (MM). Although non-selective HDAC inhibitors ...

    • Heterogeneity of genomic evolution and mutational profiles in multiple myeloma 

      Bolli, Niccolo; Avet-Loiseau, Hervé; Wedge, David C.; Van Loo, Peter; Alexandrov, Ludmil B.; Martincorena, Inigo; Dawson, Kevin J.; Iorio, Francesco; Nik-Zainal, Serena; Bignell, Graham R.; Hinton, Jonathan W.; Li, Yilong; Tubio, Jose M.C.; McLaren, Stuart; O' Meara, Sarah; Butler, Adam P.; Teague, Jon W.; Mudie, Laura; Anderson, Elizabeth; Rashid, Naim; Tai, Yu-Tzu; Shammas, Masood A.; Sperling, Adam S.; Fulciniti, Mariateresa; Richardson, Paul G.; Parmigiani, Giovanni; Magrangeas, Florence; Minvielle, Stephane; Moreau, Philippe; Attal, Michel; Facon, Thierry; Futreal, P Andrew; Anderson, Kenneth C.; Campbell, Peter J.; Munshi, Nikhil C. (Nature Pub. Group, 2014)
      Multiple myeloma is an incurable plasma cell malignancy with a complex and incompletely understood molecular pathogenesis. Here we use whole-exome sequencing, copy-number profiling and cytogenetics to analyse 84 myeloma ...

    • Identification and Validation of Ecto-5' Nucleotidase as an Immunotherapeutic Target in Multiple Myeloma 

      Ray, Arghya; Song, Yan; Du, Ting; Buon, Leutz; Tai, Yu-Tzu; Chauhan, Dharminder; Anderson, Kenneth (Springer Science and Business Media LLC, 2022-04-01)
      Interaction of plasmacytoid dendritic cells (pDCs) with multiple myeloma (MM) cells, T- or NK-effector cells in the bone marrow (BM) microenvironment induces tumor cell growth, as well as inhibits innate and adaptive immune ...

    • Identification of novel myeloma-specific XBP1 peptides able to generate cytotoxic T lymphocytes: A potential therapeutic application in multiple myeloma 

      Bae, Jooeun; Carrasco, Ruben D.; Lee, Ann-Hwee; Tai, Yu-Tzu; Anderson, Kenneth Carl; Munshi, Nikhil C. (2012)
      The purpose of these studies was to identify HLA-A2+ immunogenic peptides derived from XBP1 antigens to induce a multiple myeloma (MM)-specific immune response. Six native peptides from non-spliced XBP1 antigen and three ...

    • Identification of proteins found to be significantly altered when comparing the serum proteome from Multiple Myeloma patients with varying degrees of bone disease 

      Dowling, Paul; Hayes, Catriona; Ting, Kay Reen; Hameed, Abdul; Meiller, Justine; Mitsiades, Constantine; Anderson, Kenneth C; Clynes, Martin; Clarke, Colin; Richardson, Paul; O’Gorman, Peter (BioMed Central, 2014)
      Background: Bone destruction is a feature of multiple myeloma, characterised by osteolytic bone destruction due to increased osteoclast activity and suppressed or absent osteoblast activity. Almost all multiple myeloma ...

    • Immunomodulatory Drugs Activate NK Cells via Both Zap-70 and Cereblon-Dependent Pathways 

      Hideshima, Teru; Ogiya, Daisuke; Liu, Jiye; Harada, Takeshi; Kurata, Keiji; Bae, Jooeun; Massefski, Walter; Anderson, Kenneth (Springer Science and Business Media LLC, 2020-04-01)
      Immunomodulatory drugs (IMiDs) lenalidomide and pomalidomide show remarkable anti-tumor activity in multiple myeloma (MM) via directly inhibiting MM cell growth in the bone marrow (BM) microenvironment and promoting immune ...

    • KDM6B modulates MAPK pathway mediating multiple myeloma cell growth and survival 

      Ohguchi, Hiroto; Harada, Takeshi; Sagawa, Morihiko; Kikuchi, Shannon Adele; Tai, Yu-Tzu; Richardson, Paul Gerard Guy; Hideshima, Teru; Anderson, Kenneth Carl (Springer Nature, 2017)
      Recent studies have delineated cancer type-specific roles of histone 3 lysine 27 (H3K27) demethylase KDM6B/JMJD3 depending on its H3K27 demethylase activity. Here we show that KDM6B is expressed in multiple myeloma (MM); ...

    • Lenalidomide for the Treatment of Relapsed and Refractory Multiple Myeloma 

      Görgün, Güllü; Nijhof, Inger S; Raymakers, Reinier A; Lokhorst, Henk M; Groen, Richard W.j.; Jakubikova, Jana; Mitsiades, Constantine S; Hideshima, Teru; Laubach, Jacob; Richardson, Paul Gerard Guy; Anderson, Kenneth Carl; van de Donk, Niels WCJ (Dove Medical Press, 2012)
      Lenalidomide is an amino-substituted derivative of thalidomide with direct antiproliferative and cytotoxic effects on the myeloma tumor cell, as well as antiangiogenic activity and immunomodulatory effects. Together with ...

    • Lenalidomide Polarizes Th1-specific Anti-tumor Immune Response and Expands XBP1 Antigen-Specific Central Memory CD3+CD8+ T cells against Various Solid Tumors 

      Bae, Jooeun; Keskin, Derin B; Cowens, Kristen; Lee, Ann-Hwee; Dranoff, Glen; Munshi, Nikhil C; Anderson, Kenneth C (2016)
      Introduction: Effective combination immunotherapeutic strategies may be required to enhance effector cells’ anti-tumor activities and improve clinical outcomes. Methods: XBP1 antigen-specific cytotoxic T lymphocytes ...

    • The Medical Research Council Myeloma IX Trial: The Impact on Treatment Paradigms 

      Richardson, Paul Gerard Guy; Laubach, Jacob; Schlossman, Robert Lawrence; Ghobrial, Irene; Mitsiades, Constantine S; Rosenblatt, Jacalyn Mara; Mahindra, Anuj; Raje, Noopur; Munshi, Nikhil C; Anderson, Kenneth Carl (Blackwell Publishing Ltd, 2011)
      Osteolytic bone disease is a hallmark of symptomatic multiple myeloma. Bisphosphonates have been the mainstay of treatment to preserve skeletal integrity and prevent skeletal-related events in patients with myeloma-related ...

    • miR-29b sensitizes multiple myeloma cells to bortezomib-induced apoptosis through the activation of a feedback loop with the transcription factor Sp1 

      Amodio, N; Di Martino, M T; Foresta, U; Leone, E; Lionetti, M; Leotta, M; Gullà, A M; Pitari, M R; Conforti, F; Rossi, M; Agosti, V; Fulciniti, M; Misso, G; Morabito, F; Ferrarini, M; Neri, A; Caraglia, M; Munshi, N C; Anderson, Kenneth Carl; Tagliaferri, P; Tassone, P (Nature Publishing Group, 2012)
      MicroRNAs (miRNAs) with tumor-suppressor potential might have therapeutic applications in multiple myeloma (MM) through the modulation of still undiscovered molecular pathways. Here, we investigated the effects of enforced ...